- Home
- TYGO vs ARMP Comparison
TYGO vs ARMP Comparison
Compare TYGO & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- ARMP
- Stock Information
- Founded
- TYGO 2007
- ARMP N/A
- Country
- TYGO United States
- ARMP United States
- Employees
- TYGO N/A
- ARMP N/A
- Industry
- TYGO Semiconductors
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TYGO Technology
- ARMP Health Care
- Exchange
- TYGO Nasdaq
- ARMP Nasdaq
- Market Cap
- TYGO 53.2M
- ARMP 52.1M
- IPO Year
- TYGO N/A
- ARMP N/A
- Fundamental
- Price
- TYGO $0.85
- ARMP $1.31
- Analyst Decision
- TYGO Buy
- ARMP Strong Buy
- Analyst Count
- TYGO 3
- ARMP 1
- Target Price
- TYGO $3.00
- ARMP $7.00
- AVG Volume (30 Days)
- TYGO 19.5K
- ARMP 15.0K
- Earning Date
- TYGO 05-06-2025
- ARMP 05-20-2025
- Dividend Yield
- TYGO N/A
- ARMP N/A
- EPS Growth
- TYGO N/A
- ARMP N/A
- EPS
- TYGO N/A
- ARMP N/A
- Revenue
- TYGO $63,051,000.00
- ARMP $5,174,000.00
- Revenue This Year
- TYGO $61.65
- ARMP $8.43
- Revenue Next Year
- TYGO $28.03
- ARMP N/A
- P/E Ratio
- TYGO N/A
- ARMP N/A
- Revenue Growth
- TYGO N/A
- ARMP 14.24
- 52 Week Low
- TYGO $0.58
- ARMP $0.90
- 52 Week High
- TYGO $1.85
- ARMP $3.45
- Technical
- Relative Strength Index (RSI)
- TYGO 49.25
- ARMP 45.67
- Support Level
- TYGO $0.81
- ARMP $1.29
- Resistance Level
- TYGO $0.93
- ARMP $1.70
- Average True Range (ATR)
- TYGO 0.06
- ARMP 0.16
- MACD
- TYGO 0.01
- ARMP 0.02
- Stochastic Oscillator
- TYGO 43.26
- ARMP 18.04
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.